Vanguard Group Inc Galectin Therapeutics Inc Transaction History
Vanguard Group Inc
- $5.37 Trillion
- Q1 2025
A detailed history of Vanguard Group Inc transactions in Galectin Therapeutics Inc stock. As of the latest transaction made, Vanguard Group Inc holds 2,192,502 shares of GALT stock, worth $2.83 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,192,502
Previous 2,137,603
2.57%
Holding current value
$2.83 Million
Previous $2.54 Million
5.15%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding GALT
# of Institutions
103Shares Held
10.1MCall Options Held
587KPut Options Held
2.02M-
Black Rock Inc. New York, NY1.56MShares$2.02 Million0.0% of portfolio
-
Advisor Group Holdings, Inc. Phoenix, AZ1.22MShares$1.58 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA853KShares$1.1 Million0.0% of portfolio
-
Geneos Wealth Management Inc.423KShares$545,9730.02% of portfolio
-
Wealthspire Advisors, LLC New York, NY398KShares$513,9020.0% of portfolio
About GALECTIN THERAPEUTICS INC
- Ticker GALT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,426,000
- Market Cap $76.7M
- Description
- Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...